Using clozapine to reduce violence in people with schizophrenia.
6//7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial.
This study is looking at whether clozapine, a medication for schizophrenia, can help reduce violent behavior in people who are at high risk for violence, and it involves 280 participants over six months to see how it compares to regular treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10873816 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of clozapine, an antipsychotic medication, in reducing the risk of violent behavior among individuals with schizophrenia who are at high risk for violence. The study will involve a randomized clinical trial with 280 participants over a 24-week period, comparing clozapine treatment to standard care. By focusing on real-world community settings, the research aims to provide more generalizable results than previous studies. Participants will be monitored for violent acts, helping to determine if clozapine can significantly lower aggression levels in this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who are identified as being at high risk for violent behavior.
Not a fit: Patients with schizophrenia who are not at risk for violence or those who are not eligible for clozapine treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for individuals with schizophrenia, potentially reducing violence and enhancing public safety.
How similar studies have performed: Previous studies have suggested clozapine's effectiveness in reducing aggression, but this trial aims to provide more robust evidence through a randomized approach in community settings.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kopelowicz, Alex J — University of California Los Angeles
- Study coordinator: Kopelowicz, Alex J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.